Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence S Lamb

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Immunologic Research|August 28, 2009
Gammadelta T cells as immune effectors against high-grade gliomasLawrence S Lamb
Cytotherapy|March 14, 2013
Persistence pays off for γδ T-cell therapiesLawrence S Lamb
Hematology/Oncology Clinics of North America|July 4, 2002
Hematopoietic cellular therapy: implications for the flow cytometry laboratoryLawrence S Lamb
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2005
gammadelta T cells: a new frontier for immunotherapy?Lawrence S Lamb, Richard D Lopez
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 5, 2014
Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?Gabrielle M Siegers, Lawrence S Lamb
Cancer Immunology, Immunotherapy : CII|February 14, 2015
The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiationLarisa Pereboeva, Lualhati Harkins, Shun Wong, et al.
Frontiers in Pharmacology|December 16, 2014
Improving the safety of cell therapy products by suicide gene transferBenjamin S Jones, Lawrence S Lamb, Frederick Goldman, et al.
Plos One|May 16, 2014
Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cellsChia-Wei Chang, Yi-Shin Lai, Lawrence S Lamb, et al.
Cytometry. Part B, Clinical Cytometry|March 24, 2005
T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemiaLawrence S Lamb, Ronnie Neuberg, Jeff Welsh, et al.
Medicine|September 30, 2016
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 studyJoseph G Pressey, Julia Adams, Lualhati Harkins, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Immunologic Research|August 28, 2009
Gammadelta T cells as immune effectors against high-grade gliomasLawrence S Lamb
Cytotherapy|March 14, 2013
Persistence pays off for γδ T-cell therapiesLawrence S Lamb
Hematology/Oncology Clinics of North America|July 4, 2002
Hematopoietic cellular therapy: implications for the flow cytometry laboratoryLawrence S Lamb
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2005
gammadelta T cells: a new frontier for immunotherapy?Lawrence S Lamb, Richard D Lopez
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 5, 2014
Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?Gabrielle M Siegers, Lawrence S Lamb
Cancer Immunology, Immunotherapy : CII|February 14, 2015
The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiationLarisa Pereboeva, Lualhati Harkins, Shun Wong, et al.
Frontiers in Pharmacology|December 16, 2014
Improving the safety of cell therapy products by suicide gene transferBenjamin S Jones, Lawrence S Lamb, Frederick Goldman, et al.
Plos One|May 16, 2014
Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cellsChia-Wei Chang, Yi-Shin Lai, Lawrence S Lamb, et al.
Cytometry. Part B, Clinical Cytometry|March 24, 2005
T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemiaLawrence S Lamb, Ronnie Neuberg, Jeff Welsh, et al.
Medicine|September 30, 2016
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 studyJoseph G Pressey, Julia Adams, Lualhati Harkins, et al.
Pageof 4